Caricamento...
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...
Salvato in:
| Pubblicato in: | Pharmaceuticals (Basel) |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7766528/ https://ncbi.nlm.nih.gov/pubmed/33339404 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13120470 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|